Innovations in NSCLC Treatment

This chapter explores the latest advancements in treating non-small cell lung cancer (NSCLC), focusing on the benefits of combining chemotherapy with immunotherapy, especially in postoperative settings. Significant studies highlight improved survival rates and metrics associated with neoadjuvant therapy, emphasizing the role of circulating tumor DNA (ctDNA) in patient outcomes. The discussion also includes personalized treatment approaches based on biomarkers, alongside insights from recent trials that underline a shift in clinical practice and decision-making.